Randomised clinical trial: the 5‐HT4 agonist revexepride in patients with gastro‐oesophageal reflux disease who have persistent symptoms despite PPI therapy

BACKGROUND: A substantial proportion of patients with gastro‐oesophageal reflux disease (GERD) have only a partial response to proton pump inhibitor (PPI) therapy. Prokinetic drugs may improve reflux symptoms by enhancing oesophageal motility and gastric emptying. AIM: To evaluate the effect of reve...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaheen, N. J., Adler, J., Dedrie, S., Johnson, D., Malfertheiner, P., Miner, P., Meulemans, A., Poole, L., Tack, J., Thielemans, L., Troy, S., Vakil, N., Zerbib, F., Ruth, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Randomised Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024018/
https://www.ncbi.nlm.nih.gov/pubmed/25693609
http://dx.doi.org/10.1111/apt.13115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024018/
https://www.ncbi.nlm.nih.gov/pubmed/25693609
http://dx.doi.org/10.1111/apt.13115

Ejemplares similares